Momentum Life Sciences Announces Strategic Growth Investment from Parthenon Capital

Investment Accelerates Company’s Mission to Build the Leading Commercialization Platform Addressing Specialty Therapy Access and Adherence Challenges

INDIANAPOLIS--(BUSINESS WIRE)--Momentum Life Sciences (“Momentum” or the “Company”), a leading commercialization platform offering patient- and provider-facing solutions that support initiation and adherence for specialty therapies, announced a strategic investment from Parthenon Capital, a growth-oriented private equity firm with a long history of supporting innovative companies in healthcare solutions and technology. Following the investment, Momentum’s existing leadership team will continue as significant shareholders in the Company.

The investment will provide Momentum with strategic resources and capital to accelerate its growth strategy and pursue strategic acquisitions that support the Company’s mission to address one of the most persistent challenges facing pharmaceutical and biotechnology manufacturers, patients, and providers: enabling patients to start and stay on the specialty therapies they need.

“This is a defining moment for Momentum and the clients, patients, and providers we serve,” said Andi Heslin Smiley, President and CEO of Momentum Life Sciences. “Partnering with Parthenon provides us with additional resources and an aligned strategic partner to continue to strengthen our platform, deepen our capabilities, and take on a greater role in creating better experiences and outcomes for clients, patients, and providers, which sits at the heart of everything we do.”

Dan Killeen, a Partner at Parthenon, said, “Therapy adoption, initiation, and adherence are some of the most acute and underserved challenges facing life sciences organizations today. As therapies have become more specialized, navigating behavioral, access, financial, and operational barriers to treatment has become increasingly important. Momentum has built a differentiated platform to address these pain points, and we see a compelling opportunity to expand the Company's presence across the commercialization ecosystem.”

Patrick Hunt, a Principal at Parthenon, continued, “Momentum has built something rare: a deeply trusted clinical and human-centered platform that has proven to not only improve the patient and provider experience but also drive tangible and consistent commercial impacts for clients. We see tremendous potential in continuing the Company’s mission and expanding the role Momentum plays in supporting life sciences organizations, providers, and patients along the specialty therapy journey. We are excited to support Andi and the team as Momentum enters this next chapter of growth.”

William Blair served as financial advisor to Momentum, and Cooley served as legal counsel. Kirkland & Ellis served as legal counsel to Parthenon.

About Momentum Life Sciences
Momentum Life Sciences is a leading provider of patient support solutions. The Company drives lasting behavior change by building technology-enabled and data-driven human connections with patients and healthcare providers. Momentum’s solutions improve adherence and help providers ensure an effective patient start after the therapy decision has been made. For more information, visit www.momentumls.com.

About Parthenon Capital
Parthenon Capital is a leading growth-oriented private equity firm with offices in Boston, San Francisco, and Austin. Parthenon utilizes niche industry expertise and a deep execution team to invest in growth companies in service and technology industries. Parthenon seeks to be an active and aligned partner to management, either through recapitalization transactions or by backing new executives. Parthenon has particular expertise in financial and insurance services, healthcare and technology services, but seeks any service, technology, or delivery business with a strong value proposition and proprietary know-how. For more information, visit www.parthenoncapital.com.